Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, ...
Nasdaq

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Nasdaq

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Medical News Today

Multiple system atrophy: What to know

Multiple system atrophy (MSA) is a progressive neurological condition that affects movements and involuntary functions, such as blood pressure and digestion. The first symptoms of MSA resemble those ...
Medical Xpress

Interferon-gamma drives brain pathology in a mouse model of multiple system atrophy

Multiple system atrophy is a rare and fatal neurodegenerative disease, where insoluble inclusions of the protein alpha-synuclein appear in oligodendrocyte cells of the brain. The resulting ...
Nature

MRI-derived atrophy in multiple system atrophy aligns with mitochondrial and glial gene expression patterns

Oligodendroglial pathology is a hallmark of multiple system atrophy (MSA), yet it remains unclear whether MRI-detected atrophy reflects underlying biological mechanisms. This study investigated ...